Sponsor Overview
Explore verified public information about Catalyst Pharmaceuticals, Inc.'s expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 3 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 3 supporting sources.
“This policy describes the principles and analysis that Catalyst Pharmaceuticals, Inc. (Catalyst) will use to determine whether to grant requests for Compassionate Use Access to the products it is developing.”
“While information about the process for Compassionate Use program eligibility can be addressed to Catalyst by anyone, formal requests for Compassionate Use access to Catalyst products may only come from licensed prescribers. It is expected, though not guaranteed, that all such requests will be reviewed and a decision made within 30 days.”
“One example of this is the Expanded Access Program (EAP) that we created for our lead product. Through the EAP, any patient in the United States, within the scope of allowed diagnoses, may access the product at no charge prior to FDA approval.”
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 1 supporting sources.
Conditions: Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome, Nystagmus, Acquired
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.